Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disorders, specifically targeting cerebral folate deficiency. We view this as an interesting early-stage strategic option, supported by growing regulatory validation of folate-based therapies, although still at a preclinical stage.
LÄS MER
